David Fuller
Direttore Tecnico/Scientifico/R&S presso DIMERIX LIMITED
Patrimonio netto: 2 315 $ in data 30/06/2024
Profilo
David Fuller is currently the Chairman of EpiAxis Therapeutics Pty Ltd.
He also holds the position of Non-Executive Director at AdAlta Ltd.
since 2020 and will be the Chief Medical Officer at Dimerix Ltd.
starting in 2023.
Previously, he was the Chief Medical Officer at Race Oncology Ltd.
from 2021 to 2022.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
0.00% | 30/06/2023 | 1 899 ( 0.00% ) | 2 315 $ | 30/06/2024 |
Posizioni attive di David Fuller
| Società | Posizione | Inizio |
|---|---|---|
| ADALTA LIMITED | Direttore/Membro del Consiglio | 22/07/2020 |
| DIMERIX LIMITED | Direttore Tecnico/Scientifico/R&S | 23/10/2023 |
EpiAxis Therapeutics Pty Ltd.
 EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Presidente | - |
Precedenti posizioni note di David Fuller
| Società | Posizione | Fine |
|---|---|---|
| RACE ONCOLOGY LIMITED | Direttore Tecnico/Scientifico/R&S | 11/11/2022 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ADALTA LIMITED | Health Technology |
| RACE ONCOLOGY LIMITED | Health Technology |
| DIMERIX LIMITED | Health Technology |
| Aziende private | 1 |
|---|---|
EpiAxis Therapeutics Pty Ltd.
EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Health Technology |
- Borsa valori
- Insiders
- David Fuller
